Prolonged Scar-in-a-Jar: an in vitro screening tool for anti-fibrotic therapies using biomarkers of extracellular matrix synthesis

Autor: Sarah Rank Rønnow, Rand Qais Dabbagh, Federica Genovese, Carmel B. Nanthakumar, Vikki J. Barrett, Robert B. Good, Sarah Brockbank, Simon Cruwys, Henrik Jessen, Grith Lykke Sorensen, Morten Asser Karsdal, Diana Julie Leeming, Jannie Marie Bülow Sand

Publikováno v: Respiratory Research, Vol 21, Iss 1, Pp 1-14 (2020)

Abstract Background Idiopathic pulmonary fibrosis (IPF) is a rapidly progressing disease with challenging management. To find novel effective therapies, better preclinical models are needed for the screening of anti-fibrotic compounds. Activated fibr

Externí odkaz: https://doaj.org/article/7453a4c3b39244c08221644ac97d7ed3

Drug discovery and development in idiopathic pulmonary fibrosis: challenges and opportunities

Autor: Darcey Black, Peter Hein, Simon Cruwys, Bob Humphries

Publikováno v: Drug Discovery Today. 25:2277-2283

The pharmacological and adverse effect profiles of the two approved therapies for IPF make the development of new therapies challenging. Considering the similarity of the characteristics of drug candidates to Standard of Care is important in defining

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52d064726773cd498523240670a3f582
https://doi.org/10.1016/j.drudis.2020.09.019

Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis – Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue

Autor: Kim Henriksen, Sarah Brockbank, Diana Julie Leeming, Maria Fuglsang Bruun, Sönke Detlefsen, Sara Toftegaard Hjuler, Morten A. Karsdal, Simon Cruwys, Peter Hein, Samuel Joseph Daniels

Publikováno v: Daniels, S J, Leeming, D J, Detlefsen, S, Bruun, M F, Hjuler, S T, Henriksen, K, Hein, P, Karsdal, M A, Brockbank, S & Cruwys, S 2019, ' Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis – Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue ', Biomedicine & Pharmacotherapy, vol. 111, pp. 926-933 . https://doi.org/10.1016/j.biopha.2018.12.130
Biomedicine & Pharmacotherapy, Vol 111, Iss, Pp 926-933 (2019)

Background Non-alcoholic steatohepatitis (NASH) is a prevalent disease that is highly associated with the metabolic syndrome and type II diabetes. The development of in vivo models that reflect all nuances of the human NASH pathology is essential for

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b63455d5853c415d427ad4b91d1de90e
https://doi.org/10.1016/j.biopha.2018.12.130

Prolonged Scar-in-a-Jar:an in vitro screening tool for anti-fibrotic therapies using biomarkers of extracellular matrix synthesis

Autor: Sarah Brockbank, Grith Lykke Sørensen, Federica Genovese, Diana Julie Leeming, Jannie M.B. Sand, Henrik Jessen, Vikki J. Barrett, Sarah Rønnow, Morten A. Karsdal, Robert B. Good, Simon Cruwys, Carmel B. Nanthakumar, Rand Qais Dabbagh

Publikováno v: Rønnow, S R, Dabbagh, R Q, Genovese, F, Nanthakumar, C B, Barrett, V J, Good, R B, Brockbank, S, Cruwys, S, Jessen, H, Sorensen, G L, Karsdal, M A, Leeming, D J & Sand, J M B 2020, ' Prolonged Scar-in-a-Jar : an in vitro screening tool for anti-fibrotic therapies using biomarkers of extracellular matrix synthesis ', Respiratory Research, vol. 21, 108 . https://doi.org/10.1186/s12931-020-01369-1
Respiratory Research, Vol 21, Iss 1, Pp 1-14 (2020)
Respiratory Research

Background Idiopathic pulmonary fibrosis (IPF) is a rapidly progressing disease with challenging management. To find novel effective therapies, better preclinical models are needed for the screening of anti-fibrotic compounds. Activated fibroblasts d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd4bca4d89576887e6d121d1b78582a7
https://findresearcher.sdu.dk:8443/ws/files/169994955/Open_Access_Version.pdf

Clinically validated markers of the extracellular matrix remodelling are altered by potential anti-fibrotic compounds in a human lung fibrosis ex vivo model

Autor: Morten A. Karsdal, Sarah Rønnow, Christina Hesse, Sarah Brockbank, Armin Braun, Simon Cruwys, Diana Julie Leeming, Sebastian Konzok, Katherina Sewald, Jannie M.B. Sand

Background: Pulmonary fibrosis (PF) is characterized by excessive extracellular matrix (ECM) remodeling. Clinically validated ECM neoepitopes markers, related to progressive PF, may be useful for the evaluation of potential anti-fibrotic effects. Aim

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9bbf523668e8e3a0206514af43804f34
https://publica.fraunhofer.de/handle/publica/259290